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Abstract 
Review on GSTA1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: GST2, GSTA1-1, GTH1 
HGNC (Hugo): GSTA1 
Location: 6p12.2 
Local order 
Between the LOC647169 (similar to glutathione 
transferase) and GSTA6P (glutathione S-transferase 
alpha 6 pseudogene) (according to PubMed). 
Note 
The GSTA1 gene is composed of 7 exons spanning 
a region of 12487 bases. 
DNA/RNA 
Note 
The human alpha class genes are located in a cluster 
on chromosome 6p12 and comprise five functional 
genes (GSTA1, GSTA2, GSTA3, GSTA4, GSTA5) 
and seven pseudogenes (Morel et al., 2002). 
Description 
The GSTA1 gene is approximately 12 kb in length 
and is closely flanked by other alpha class gene 
sequences. The complete sequence of the 1,7-kb 
intergenic region between exon 7 of an upstream 
pseudogene and exon 1 of the GSTA1 gene has 
been determined (Suzuki et al., 1993). 
Transcription 
The 1276-nucleotide transcript encodes a protein of 
222 amino acid residues. 
Pseudogene 
An additional gene that encodes an uncharacterized 
Alpha class GST has been identified. The protein 
derived from this gene would have 19 amino acid 
substitutions compared with the GSTA1 isoenzyme. 
Several pseudogenes with single-base and/or 
complete exon deletions have been identified, but 
no reverse-transcribed pseudogenes have been 
detected (Suzuki et al., 1993). 
 
 
GSTA1 gene. The GSTA1 gene spans a region of 12,5 kb composed of the seven exons (red) and six introns (green). Exons 1, 
2, 3, 4, 5, 6 and 7 are 59 bp, 117 bp, 52 bp, 133 bp, 142 bp, 132 bp and 198 bp in length, respectively. 
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Crystal structure of human glutathione transferase (GST) A1-1 in complex with glutathione. Adapted from PDB (Grahn et 
al., 2006). 
 
Polymorphisms: GSTA1 has a functional three 
apparently linked single nucleotide polymorphisms 
(SNPs) in an SP1-responsive element within the 
proximal promoter (G-52A, C-69T and T-567G), 
plus at least four SNPs further upstream and a silent 
SNP A-375G. Two variants, GSTA1*A (-567T, -
69C,-52G) and GSTA1*B (-67G, -69T, -52A), have 
been named according to the linked functional 
SNPs. Specifically, these substitutions result in 
differential expression with lower transcriptional 
activation of variant GSTA1*B than common 
GSTA1*A allele. It has been suggested that this 
genetic variation can change an individual's 
susceptibility to carcinogens and toxins, as well as, 
affect the efficacy of some drugs (Coles and 
Kadlubar, 2003). In addition, the linkage 
disequilibrium between GSTA1*A/GSTA1*B and 
GSTA2G335C (Ser112Thr) has been shown in 
Caucasians: specifically, GSTA1*A/GSTA2C335 
(Thr112) and GSTA1*B/GSTA2G335 (Ser112) 
(Ning et al., 2004). It seems that the higher hepatic 
expression of GSTA1 enzyme in homozygous 
GSTA1 individuals is associated with the lower 
hepatic expression of GSTA2 in GSTA2C335 
(Thr112) individuals (Coles et al., 2001a; Ning et 
al., 2004). Other haplotypes within this 
nomenclature but including SNPs C-115T, T-631G, 
and C-1142G also have been proposed 
(Bredschneider et al., 2002; Guy et al., 2004). 
Polymorphisms upstream of G-52C seem to have 




Glutathione S-transferase A1 is N-terminally 
processed. 
Amino acids: 222. 
Calculated molecular mass: 25,63 kDa. 
Description 
The active GSTA1-1 enzyme is a homodimer, with 
each subunit containing a GSH-binding site (G-site) 
and a second adjacent hydrophobic binding site for 
the electrophilic substrate (H-site) (Wilce and 
Parker, 1994).  
The C-terminal region of GSTA1-1 contributes to 
the catalytic and noncatalytic ligand-binding 
functions of the enzyme, while the conserved G-site 
is located in the N-terminal domain (Balogh et al., 
2009).  
Protein flexibility and dynamics in a molten 
globule-active site including the C-terminal α9 
helix and the protruding ends of the α4-α5 helices 
result in achieving remarkable catalytic promiscuity 
of GSTA1-1 (Wu and Dong, 2012; Honaker et al., 
2013). It has been proposed that the α9 helix may 
function as a mobile gate to the active-site cavity, 
controlling substrate access and product release. 
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Structure determination and refinement of human alpha class glutathione transferase A1-1, and a comparison with the 




GSTA1-1 is highly expressed (as mRNA and 
protein) in liver, intestine, kidney, adrenal gland, 
pancreas and testis, while expression in a wide 
range of tissues is low (Hayes and Pulford, 1995; 
Coles et al., 2001a). Both positive and negative 
regulatory regions are present in the 5` noncoding 
region of GSTA1, including a polymorphic SP1-
binding site within the proximal promoter. Binding 
of the transcription factor AP1 has been suggested 
as a common mechanism for up-regulation of GSTs 
(Hayes and Pulford, 1995). The results of recent 
study also implied the role of a Kelch-like ECH-
associated protein 1 (Keap1)-dependent signaling 
pathway for the induction of the constitutive 
GSTA1 expression during epithelial cell 
differentiation (Kusano et al., 2008). Regarding 
GSH-dependent ∆5-∆4 isomerase activity of this 
class of enzyme, it has been shown that 
steroidogenic factor 1 (SF-1) is involved in 
regulation of expression of GSTA genes 
(Matsumura et al., 2013). Aberrant overexpression 
has been observed in various malignancies such as 
colorectal (Hengstler et al., 1998) and lung cancer 
(Carmichael et al., 1988), while decrease in alpha 
class GSTs has been observed in stomach and liver 
tumors (Howie et al., 1990). A detailed recent 





Human GSTA1-1 enzyme catalyzes the GSH-
dependent detoxification of electrophiles showing 
highly promiscuous substrate selectivity for many 
structurally unrelated chemicals, including 
environmental carcinogens (e.g. benzo(a)pyrene 
diol epoxides), several alkylating chemotherapeutic 
agents (such as busulfan, chlorambucil, melphalan, 
phosphoramide mustard, cyclophosphamide, 
thiotepa), as well as, steroids and products of lipid 
degradation. GSTA1-1 is the most highly expressed 
GST of the liver and could therefore, be critical for 
"systemic" detoxification of electrophilic 
xenobiotics including carcinogens and drugs (Coles 
and Kadlubar, 2005).  
In addition to enzymatic detoxification, GSTA1 
acts as modulator of mitogen-activated protein 
kinase (MAPK) signal transduction pathway via a 
mechanism involving protein-protein interactions. 
Namely, GSTA1 forms complexes with c-Jun N-
terminal kinase (JNK), modifying JNK activation 
during cellular stress (Adnan et al., 2012).  
Thus, it is possible that GSTA1 confer drug 
resistance by two distinct means: by direct 
inactivation (detoxification) of chemotherapeutic 
drugs and by acting as inhibitors of MAPK 
pathway. 
Homology 
The alpha class GSTs is showing strong intra-class 
sequence similarity (Balogh et al., 2009). 
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Mutations 
Germinal 
None described so far. 
Somatic 
36 mutations (COSMIC): 26 substitution-missense, 
4 substitution-nonsense, 5 substitution-coding 




Regarding the role of GSTA1 polymorphism in the 
risk of colorectal cancer, the results of 
epidemiological studies are still inconclusive. 
Several studies showed that GSTA1*B genotype 
(low hepatic expression) is associated with 
increased susceptibility to colorectal cancer, which 
imply the possible inefficient hepatic detoxification 
of food-derived carcinogen metabolite N-acetoxy-
PhIP (Coles et al., 2001b; Sweeney et al., 2002). In 
contrast, meta-analysis of Economopoulos 
representing the pooled analysis of four studies 




The role of GSTA1 polymorphism in breast cancer 
risk was mainly based on investigation on response 
to chemotherapeutic drugs in these patients. In 
breast cancer patients on cyclophosphamide 
containing chemotherapy carriers of GSTA1*B/*B 
genotype showed significantly reduced five years 
risk of death in comparison to GSTA1*A 
homozygous carriers. This association was likely 
caused by decreased detoxification of the 
therapeutic metabolites of cyclophosphamide in 
GSTA1*B/*B patients (Sweeney et al., 2003). 
Bladder cancer 
Note 
Recent investigation indicates that the GSTA1-low 
activity genotype in combination with the GSTM1-
null genotype significantly increases the risk of 
bladder cancer in smokers (Matic et al., 2013). In 
addition, it seems that GSTA1 polymorphism may 
influence vulnerability to oxidative DNA damage, 
thereby contributing to the malignant potential of 




Aberant overexpression of both GSTA1 and 
GSTA2 proteins was found in blast cells derived  
from acute myeloid leukemia patients, showing 
resistance to doxorubicin in vitro (Sargent et al., 
1999). In addition, GSTA1 and CYP39A1 (member 
of cytochrome P450 family) polymorphisms were 
found to be associated with pharmacokinetics of 
busulfan, which is used in preparative regimens 
prior to stem cell transplantation in pediatric 
patients (ten Brink et al., 2013). 
Prostate cancer 
Note 
Genetic variants of GSTA1 and GSTT1 may 
modify prostate cancer risk, especially among 
smokers (Komiya et al., 2005). 
Asthma 
Note 
Genetic alterations in GST enzymes may influence 
the detoxification of environmental toxic 
substances in airway and increase the risk of 
asthma.  
Thus, it has been shown that subjects with at least 
one allele -69T in the GSTA1 genotype have an 
increased risk of asthma (Polimanti et al., 2010). 
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